Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Tasly pays up to $65mm for Chinese rights to Mesoblast's MPC150IM and MPC25IC cardio candidates

Executive Summary

Tasly Pharmaceutical Co. Ltd. licensed exclusive rights in China to develop, manufacture, and commercialize Mesoblast Ltd.'s allogeneic mesenchymal precursor cell (MPC) cardiovascular disease candidates MPC150IM and MPC25IC.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies